Filing Flows › Coherus Oncology (CHRS) › Q1 2025
Coherus Oncology (CHRS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Coherus Oncology (CHRS) reported revenue of $7.6M for the first quarter 2025 (Q1 2025), +229% from a year earlier and -86% from the quarter before. Operating margin was -597.9%, net loss $56.6M (744.4% of revenue).
Coherus Oncology, Q1 2025: revenue $7.6M (+229% year over year), operating margin -597.9%, net loss $56.6M, operating cash flow −$25.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.6M | -86% | +229% |
| Operating profit | −$45.4M | — | — |
| Net earnings | −$56.6M | — | — |
| Operating cash flow | −$25.8M | -190% | — |
What changed
Revenue was $7.6M in Q1 2025, up 229% year over year and down 86% from the previous quarter. Toripalimab was the largest line at 97% of revenue. Toripalimab added $5.4M year over year (up 270%), 101% of the total change. Other revenue declined 22%.
Operating costs exceeded revenue by $45.4M, an operating margin of -597.9%. Total costs fell 24% while revenue rose 229%. The fastest-growing cost line was Cost of revenue (+84%). The quarter ended with a net loss of $56.6M, wider than the previous quarter's $50.7M loss.
Operating cash flow was −$25.8M. Non-cash charges added back $400K of depreciation and amortization and $5.4M of share-based compensation. Working capital and other items added $25.0M.
Questions
What was Coherus Oncology's revenue in the first quarter 2025?
Coherus Oncology (CHRS) reported revenue of $7.6M for the first quarter 2025 (Q1 2025), +229% from a year earlier and -86% from the quarter before.
Was Coherus Oncology profitable in the first quarter 2025?
Operating loss was $45.4M (-597.9% of revenue) and net loss $56.6M.
Source: Coherus Oncology 10-Q on SEC EDGAR.